Imbria touts PhII success in hypertrophic cardiomyopathy, adding fuel to overall efficacy profile

Im­bria Phar­ma­ceu­ti­cals’ par­tial fat­ty acid ox­i­da­tion in­hibitor im­proved out­comes in Phase II non-ob­struc­tive hy­per­trophic car­diomy­opa­thy pa­tients, with the com­pa­ny not­ing that the as­set’s ef­fi­ca­cy could bode well for up­com­ing re­sults in a sep­a­rate heart fail­ure tri­al.

Non-ob­struc­tive hy­per­trophic car­diomy­opa­thy (nHCM) af­fects around one in 500 peo­ple, ac­cord­ing to the Amer­i­can Heart As­so­ci­a­tion, with a third of cas­es be­ing non-ob­struc­tive. But heart fail­ure with pre­served ejec­tion frac­tion (HF­pEF) af­fects more peo­ple, with an es­ti­mat­ed 2% of the pop­u­la­tion. Im­bria’s nin­er­afax­s­tat is in Phase II de­vel­op­ment for both con­di­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.